A recent review examined targeted protein degradation technologies and their biological impacts across health and species, outlining therapeutic promise alongside ecological and safety considerations. Authors Yue, He, and Hou synthesize evidence that small‑molecule degraders can selectively remove disease‑causing proteins, but also note off‑target degradation and variable species responses that create translational and environmental risk. The paper calls for expanded safety testing and cross‑species impact assessment as degrader modalities move from lab to clinic and production.